Efficacy and safety study of subcutaneous injection of bortezomib in the treatment of de novopatient

• 作 者: 刘辉
• 机 构: 1st Affil Hosp,Soochow Univ,Jiangsu Instit Hema-tol,Key Lab of Thrombosis&Hemostasis,Health Minis-tr
• 出 处: China Medical Abstracts(Internal Medicine)
• 发表日期: 2013年04期
• 关键词: subcutaneous myeloma adriamycin curative remission neuropathy intravenous diarrh

Objective To explore the efficacy and safety of subcutaneous injection of bortezomib in the treatment of de novo multiple myeloma (MM) patients.Methods A total of 36 MM patients treated with bortezomib,adriamycin and dexamethason (PAD) from January 2012 to April2013 were analyzed.Among them,18 received improved PAD (improved PAD group) with the subcutaneous injection of bortezomib,another 18 received conventional PAD (PAD group) .The efficacy and safety of two groups

Objective To explore the efficacy and safety of subcutaneous injection of bortezomib in the treatment of de novo multiple myeloma (MM) patients. Methods A total of 36 MM patients treated with bortezomib, adriamycin and dexamethason (PAD) were analyzed from January 2012 to April 2013. Among them, 18 received improved PAD (improved PAD group) with the subcutaneous injection of bortezomib, another 18 received conventional PAD (PAD group). The efficacy and safety of two groups